Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|October 7, 2009
Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemiaCrisoula Batzios, Lachlan A Hayes, Simon Z He, et al.
Ejhaem|April 28, 2025
Enhanced Disease Detection of Hairy Cell Leukaemia Through Next-Generation Sequencing Based BRAF V600E and Phased Variant AnalysisSimon Wu, Tamia Nguyen, Imogen Caldwell, et al.
Ejhaem|November 29, 2023
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemiaSean Harrop, Phillip C Nguyen, David Byrne, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Internal Medicine Journal|July 2, 2025
Design, implementation and evaluation of a model of care for patients with germline predisposition to haematological malignancy and bone marrow failure syndromesLucy C Fox, Erin Goode, Nicole Den Elzen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2019
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution seriesIsaac Goncalves, Kate Burbury, Michael Michael, et al.
Ejhaem|January 27, 2025
A novel TERT variant associated with a telomere biology disorder and challenges in variant classificationVahid Pazhakh, Lucy C Fox, Nicole Den Elzen, et al.
Leukemia|February 17, 2026
Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasetsIng Soo Tiong, Sally Hunter, Yamuna Kankanige, et al.
Blood Advances|October 24, 2023
The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencingAnna Maierhofer, Nikita Mehta, Ryan A Chisholm, et al.
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Pageof 16